



SERODUS

SERODUS AS

**Group Interim Financial Report
Fourth Quarter 2023**

(Unaudited)

January 2024

Q4 2023 Highlights for Serodus Lead project.

- After an initial increasing in screening and randomization activities of patients to the SER150 CL-009 study in New Zealand this has slowed down.
- Recruitment of patients in Australia remains very slow.
- Private Placement of 1,3 mil B-shares was completed and the proceeds of app. NOK 17 received. It was furthermore decided to do a Subsequent Offering of B-shares in early 2024.

SER150 for Diabetic Kidney Disease

Management of SER150 is outsourced to Serodus ApS.

Today 20 patients are randomized to the SER150 CL-009 study, and the last patient randomized is expected to be finalized in August 2024.

Management is as sponsor responding to questions from the clinical centres involve when screening patients and during the treatment period.

Patents

Management has identified new patentable results from a previous pharmacological study with SER150.

Dual TNFR1 Antagonists and TNFR2 Agonists for use in renal disease

- Medical use claims covering SER150 for use in treatment of renal diseases in certain patient populations.
- Filing date 12 Nov 2021.
- The patent is granted in Europe and is in force in Germany, Spain, France, Great Britain, Italy, Netherlands and Poland.
- Patent applications are pending in USA, Japan, China, Canada and Australia.

Substituted 1,3-Dioxanes useful as PPAR modulators.

- Composition of matter patent.
- Filing date 18.01.2008.

The patent is in force in Germany, Spain, France, Great Britain and Italy, Canada, China and USA.

SER130 for treatment of Diabetic Kidney Disease

No additional pre-clinical or preclinical studies have been performed.

Management has identified new patentable results from a previous pharmacological study with SER130.

IL-4 Derived peptide fragments for use in the treatment of diabetic nephropathy

- Medical use claims covering SER130 for use in the treatment of diabetic nephropathy.
- Filing April 2023.
- Positive International Preliminary Report on Patentability from PCT.
- The application will enter into national phase in October/November 2024 in countries to be decided.

IL-4-Derived peptides for modulation of the chronic inflammatory response and treatment of autoimmune diseases

- Composition-of-matter patent.
- Filing 2009.

The patent is in force in Germany, Spain, France, Great Britain and Italy, Canada, Japan and USA.

SER140 for treatment of Diabetic Kidney Disease

No additional pre-clinical or preclinical studies have been performed.

Management has identified new patentable results from a previous pharmacological study with SER130.

IL1RA derived peptides for treatment of diabetic nephropathy

- Medical use claims covering SER140 for use in the treatment of diabetic nephropathy.
- Filing 2021.
- Positive International Preliminary Report on Patentability from PCT.
- The application will enter into national phase in January 2024 in Australia, Canada, China, Europe, Japan and the USA.

Antagonists of the Interleukin- 1 receptor

- Composition-of-matter patent.
- Filing 2012.
- The patent is in force in Germany, Spain, France, Great Britain and Italy, Japan and USA.

Financials

Please find below the financial statement for the fourth quarter of 2023 compared to same quarter in 2022.

At the end of the fourth quarter of 2023 Serodus had app. NOK 23,5 M in cash.

The company raised app. NOK 17 M in a Private Placement by issuing app. 1,3 M preference B-shares. This was formally approved on an EGM on the 2nd of October 2023.

In December the Boards of Directors decided to do a Subsequent Offering of B-shares on the same conditions as the Private Placement in October 2023. The offering will take place in the first quarter in 2024.

Profit & Loss

(All figures in thousand NOK)	Q4 '2023	Q4 '2022	YTD 2023	YTD 2022
Operating income				
Revenue	-	-	-	-
Cost of goods sold	-	-	-	-
Gross Profit	-	-	-	-
Operating expenses				
Cost of sales	-	-	-	-
Project cost	(12,441)	(2,933)	(16,935)	(14,375)
Personnel expenses	(1,069)	(629)	(2,400)	(2,481)
Depreciation and Amortization of assets	-	(11)	()	(42)
Other Operating Expenses	(1,377)	(1,164)	(4,159)	(4,489)
Total Operating Expenses	(14,887)	(4,736)	(23,494)	(21,386)
Operating result	(14,887)	(4,736)	(23,494)	(21,386)
Net finance	(81)	3	(274)	(629)
Profit/ (loss) before tax	(14,968)	(4,733)	(23,768)	(22,015)
Tax	-	-	-	-
Profit/ (loss) after tax	(14,968)	(4,733)	(23,768)	(22,015)

Balance Sheet

(All figures in thousand NOK)

	31-12-2023	31-12-2022
ASSETS		
<i>Assets</i>		
Intangible assets	-	512
Goodwill	-	-
Sum intangible assets	-	512
<i>Current assets</i>		
Inventories	2,701	6,748
Other short term receivables	3,141	8,205
Bank	23,475	21,779
Sum Current assets	29,317	36,733
Sum assets	29,317	37,245
EQUITY AND DEBT		
Share capital	18,402	17,073
Share premium reserve	-	-
Other equity	36,039	88,167
Capital not registered		
Retained earnings	(27,276)	(71,813)
Sum equity	27,165	33,427
<i>Long term debt</i>		
Convertible loan	-	-
Deferred tax	-	-
Sum long term debt	-	-
<i>Short term debt</i>		
Accounts payable	1,694	303
Other short term debt	458	3,515
Sum short term debt	2,152	3,818
Sum equity and debt	29,317	37,245

Cash flow

(All figures in thousand NOK)

	Q4 '2023	Q4 '2022	YTD 2023	YTD 2022
Cash flow from operating activities				
Ordinary profit/(loss) before tax	(14,968)	(4,733)	(23,768)	(22,015)
Amortization of assets				
Depreciation of assets	-	11		42
Placement expenses booked directly to equity				
Share based payments				
Changes in accounts receivables, creditors and inventory	5,208	(848)	1,484	(453)
Changes in accruals	(312)	2,320	6,034	692
Net cash flow from operating activities	(10,072)	(3,251)	(16,250)	(21,734)
Cash flow from investing activities				
Investment in assets	-	-	-	-
Net cash flow from investing activities	-	-	-	-
Cash flow from financing activities				
Proceeds from issue of share capital	17,272	-	17,272	325
Capital not registered				
Convertible loan	-	-	-	-
Emmision acquisition of shares Phlogo				
Issue expences recognized directly in equity				
Repayment of loans				
Net cash flow from financing activities	17,272	-	17,272	325
Net changes in cash and cash equivalents	7,200	(3,251)	1,022	(21,409)
Cash and cash equivalents at the beginning of the period	16,275	25,030	22,453	43,189
Cash and cash equivalents at the end of the period	23,475	21,779	23,475	21,779

Equity

YTD 2023

(All figures in thousand NOK)	Share capital	Share premium reserve	Other paid in equity	Retained earnings	Total equity
Equity 01.01.2023	17,073	-	20,096	-	37,169
- Profit/(loss) for the period				(23,768)	(23,768)
- Other revenue/expenses				-	-
<i>Total comprehensive income</i>	-	-	-	(23,768)	(23,768)
<i>Transaction costs</i>					-
Sharebased payments					-
Conversion of debt					-
Capital not registered					-
Issue of shares	1,329		15,943		17,272
Foreign exchange change Equity /Other changes				(3,508)	(3,508)
Capital reduction					-
Equity 31.12.2023	18,402	-	36,039	(27,276)	27,165

Key Figures

(All figures in thousand NOK)	Q4 '2023	Q4 '2022	YTD 2023	YTD 2022
Total operating revenue	-	-	-	-
Total Gross Profit	-	-	-	-
Net operating expenses	(14,887)	(4,736)	(23,494)	(21,386)
Operating profit (loss)	(14,887)	(4,736)	(23,494)	(21,386)
Total comprehensive income(loss) for the period	(14,968)	(4,733)	(23,768)	(22,015)
Diluted earnings (loss) per share	(0.81)	(0.28)	(1.29)	(1.29)
Number of employees	2	2	2	2
Cash and equivalents at end of period	23,475	21,779	23,475	21,779

Board of Directors and CEO
January 2024
Serodus AS